209 related articles for article (PubMed ID: 19074883)
21. Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells.
Roche C; Rasolonjanahary R; Thirion S; Goddard I; Fusco A; Figarella-Branger D; Dufour H; Brue T; Franc JL; Enjalbert A; Barlier A
Hum Gene Ther; 2012 Jan; 23(1):104-14. PubMed ID: 21942649
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
[TBL] [Abstract][Full Text] [Related]
23. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
24. Structure-function correlations of growth hormone or/and prolactin-producing pituitary adenomas: an in vitro study with the reverse hemolytic plaque assay.
Thodou E; Kontogeorgos G; Kyrodimou E; Salla H; Ramyar L; Vamvassakis E; Piaditis G; Anagnostopoulos N; Tzanis S; Levedis A; Rologis D; Asa SL
J Endocrinol Invest; 1999 Oct; 22(9):671-80. PubMed ID: 10595830
[TBL] [Abstract][Full Text] [Related]
25. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
Losa M; Mortini P; Giovanelli M
Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
[TBL] [Abstract][Full Text] [Related]
26. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.
Zhou C; Jiao Y; Wang R; Ren SG; Wawrowsky K; Melmed S
J Clin Invest; 2015 Apr; 125(4):1692-702. PubMed ID: 25774503
[TBL] [Abstract][Full Text] [Related]
27. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide.
Gonzalez B; Vargas G; Ramirez C; Asa S; Cheng S; Sandoval C; Mercado M
Endocrinol Nutr; 2014 Dec; 61(10):523-30. PubMed ID: 25008035
[TBL] [Abstract][Full Text] [Related]
28. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I
J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
[TBL] [Abstract][Full Text] [Related]
30. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.
Plöckinger U; Albrecht S; Mawrin C; Saeger W; Buchfelder M; Petersenn S; Schulz S
J Clin Endocrinol Metab; 2008 Apr; 93(4):1203-10. PubMed ID: 18198230
[TBL] [Abstract][Full Text] [Related]
31. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
32. A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies.
Saveanu A; Morange-Ramos I; Gunz G; Dufour H; Enjalbert A; Jaquet P
Eur J Endocrinol; 2001 Jul; 145(1):35-41. PubMed ID: 11415850
[TBL] [Abstract][Full Text] [Related]
33. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity.
Barlier A; Pellegrini-Bouiller I; Gunz G; Zamora AJ; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1999 Aug; 84(8):2759-65. PubMed ID: 10443675
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
35. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
[TBL] [Abstract][Full Text] [Related]
36. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
37. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy.
Ferone D; de Herder WW; Pivonello R; Kros JM; van Koetsveld PM; de Jong T; Minuto F; Colao A; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2008 Apr; 93(4):1412-7. PubMed ID: 18211974
[TBL] [Abstract][Full Text] [Related]
38. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2.
Ferrante E; Pellegrini C; Bondioni S; Peverelli E; Locatelli M; Gelmini P; Luciani P; Peri A; Mantovani G; Bosari S; Beck-Peccoz P; Spada A; Lania A
Endocr Relat Cancer; 2006 Sep; 13(3):955-62. PubMed ID: 16954443
[TBL] [Abstract][Full Text] [Related]
39. Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas.
Hofland LJ; de Herder WW; Waaijers M; Zuijderwijk J; Uitterlinden P; van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1999 Sep; 84(9):3336-43. PubMed ID: 10487708
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
